BridgeMD
New treatment option for Metabolic Dysfunction-Associated Steatotic Liver Disease
Official title A Large Language Model-based Chatbot for Alcohol Reduction in Patients With Metabolic Alcohol-Related Liver Disease
ClinicalTrials.gov ID: NCT07450144
What this study is testing
- What it's testing
- The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of LLM-based chatbot for reducing alcohol use among patients with metabolic alcohol-related liver disease. Specific objectives include: 1.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 1\. Hong Kong residents aged 18 years or above 2. Diagnosed of MASLD:
- Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic...
- Presence of metabolic dysfunction, indicated by at least one of the following:
- Overweight or obesity (body mass index [BMI] ≥25 kg/m²),
- Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides [≥150 mg/dL] or low high-density lipoprotein [HDL] cholesterol [\<40 mg/dL for men...
You likely can't join if
- Diagnosed with mental disease or cognitive impairments, or
- Participating in other ongoing clinic trials
See the full eligibility criteria
- 1\. Hong Kong residents aged 18 years or above 2. Diagnosed of MASLD:
- Evidence of hepatic steatosis (fat accumulation in the liver) confirmed by imaging techniques such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), or liver biopsy
- Presence of metabolic dysfunction, indicated by at least one of the following:
- Overweight or obesity (body mass index [BMI] ≥25 kg/m²),
- Type 2 diabetes mellitus, ③Dyslipidemia (elevated triglycerides [≥150 mg/dL] or low high-density lipoprotein [HDL] cholesterol [\<40 mg/dL for men, \<50 mg/dL for women]), ④Hypertension (blood pressure ≥130/85 mmHg or...
- Metabolic syndrome as defined by established criteria (e.g., International Diabetes Federation [IDF], Adult Treatment Panel III [ATP III]) 3. Alcohol consumption: males who drink 210-420 g/week (≈263-525 ml), female who...
- Diagnosed with mental disease or cognitive impairments, or
- Participating in other ongoing clinic trials
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.